STEMEZ hN2 Human Neurons-electro-physiology data.
About Gray
1994-present-President, ICT
1993-1996-Conjugation Chemist, R&D Systems
19989-1993-Supervisor Protein Conjugation & ELISA Development Group, Solvay Animal Health
1986-1989-Immunologists, Biosciences Lab, 3M
1976-1986-Various Lab, U of MN
Gary’s Conatct Info:
gary@immunochemistry.com
952-888-8788
Inventing Better Ways to Measure Apoptosis
This profile features another Scientist Entrepreneur. Dr Gary Johnson is the Founder and President of Immunochemistry Technologies LLC (ICT). His company manufactures kits that have the [...]
ArunA Biomedical, Inc. announces alliance with Neuromics for distribution of normal human neural cells.
I have featured Steve Stice and his team at ArunA Biomedical and UGA. They are pioneers in developing Embryonic Stem Cell Based Cultures and Assays for Drug Discovery and Basic Research. Given the importance of their work, I am commited to keeping my finger on the pulse of their advances and discoveries.
Here they isolate, and maintain in [...]
Just wanted to update you on my friends at Dicerna…from in vivo blog…
Wednesday, October 31, 2007
Dicerna Crashes RNAi Party
Life often imitates art, as the saying goes.
In “This Is Spinal Tap,” the classic rock and roll mockumentary chronicling the eponymous band, guitarist Nigel Tufnel famously brags that his amplifiers, unlike conventional ones that max out at [...]
Dr Steve Stice and Human Stem Cells
I am pleased and honored for the privilege of profiling Dr. Steve Stice. He has a history of working in areas that are Biotechnology Headliners…from cloning to stem cells. Here I will be focusing on his current work with Human Stem Cells and Neural Progenitors at ArunA Biomedical and [...]
As a follow on to the potential of 27mer DsiRNAs as a key platform for drug discovery and development, we are happy to report:
15.07.2008 13:34
Dicerna Pharmaceuticals, a Second Generation RNA Interference Company, Completes Second Closing of Series A Financing; Unveils Strategic Focus
Dicerna Pharmaceuticals, Inc. (www.dicerna.com), an RNA interference company developing novel therapeutics utilizing proprietary [...]
